论文部分内容阅读
目的:探讨反流性食管炎患者采用莫沙必利联合奥美拉唑的治疗效果。方法:收集2014年2月-2015年2月我院诊断为反流性食管炎的患者,按按住院单双号顺序分为2组:100例研究组(接受莫沙必利联合奥美拉唑)和100例对照组(接受莫沙必利联合雷贝拉唑)。对比(1)研究组和对照组治疗前、后反流性食管炎的内镜分级。(2)研究组和对照组反流性食管炎的治疗疗效。结果:(1)研究组和对照组治疗前反流性食管炎内镜分级,结果比较无差异(P>0.05),研究组和对照组治疗后反流性食管炎内镜分级结果比较无差异(P>0.05)。(2)研究组和对照组反流性食管炎治疗有效率分别为92%、78%,结果比较无差异(P>0.05)。结论:本次研究认为本次研究认为莫沙必利联合奥美拉唑治疗反流性食管炎疗效肯定,值得临床推广。
Objective: To investigate the therapeutic effect of mosapride and omeprazole in patients with reflux esophagitis. Methods: The patients diagnosed as reflux esophagitis in our hospital from February 2014 to February 2015 were divided into two groups according to the sequence of hospital admission orders: 100 study groups (receiving mosapride and omeprazole Azole) and 100 control groups (receiving mosapride and rabeprazole). Comparison (1) Endoscopic classification of reflux esophagitis in study group and control group before and after treatment. (2) Therapeutic effect of reflux esophagitis in study group and control group. Results: (1) Endoscopic classification of reflux esophagitis before treatment in study group and control group showed no significant difference (P> 0.05). There was no difference in endoscopic grade of reflux esophagitis between study group and control group (P> 0.05). (2) The effective rates of reflux esophagitis in study group and control group were 92% and 78% respectively, there was no difference between the two groups (P> 0.05). Conclusion: This study suggests that this study concluded that mosapride combined with omeprazole treatment of reflux esophagitis positive effect, worthy of clinical promotion.